These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


205 related items for PubMed ID: 11595198

  • 1. Insulin resistance syndrome and type 2 diabetes mellitus.
    Erkelens DW.
    Am J Cardiol; 2001 Oct 11; 88(7B):38J-42J. PubMed ID: 11595198
    [Abstract] [Full Text] [Related]

  • 2. Diabetic dyslipidemia.
    Kreisberg RA.
    Am J Cardiol; 1998 Dec 17; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Dec 17; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
    Falko JM, Moser RJ, Meis SB, Caulin-Glaser T.
    Curr Diabetes Rev; 2005 May 17; 1(2):127-35. PubMed ID: 18220588
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M.
    Nutr Metab Cardiovasc Dis; 2002 Feb 17; 12(1):29-35. PubMed ID: 12125227
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 17; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 11. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J.
    Can J Cardiol; 1998 May 17; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [Abstract] [Full Text] [Related]

  • 12. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul 17; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
    Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Bracs P, Black D.
    Am J Cardiol; 1997 Jul 01; 80(1):39-44. PubMed ID: 9205017
    [Abstract] [Full Text] [Related]

  • 15. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
    Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, Tomassini JE, Tershakovec AM.
    Mayo Clin Proc; 2006 Dec 01; 81(12):1579-88. PubMed ID: 17165637
    [Abstract] [Full Text] [Related]

  • 16. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
    Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H.
    Diabet Med; 2011 Jul 01; 28(7):856-64. PubMed ID: 21244474
    [Abstract] [Full Text] [Related]

  • 17. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 01; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 18. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
    Davidson M, Ma P, Stein EA, Gotto AM, Raza A, Chitra R, Hutchinson H.
    Am J Cardiol; 2002 Feb 01; 89(3):268-75. PubMed ID: 11809427
    [Abstract] [Full Text] [Related]

  • 19. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
    Wolffenbuttel BH, Franken AA, Vincent HH, Dutch Corall Study Group.
    J Intern Med; 2005 Jun 01; 257(6):531-9. PubMed ID: 15910557
    [Abstract] [Full Text] [Related]

  • 20. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
    Wanner C, Krane V.
    Am J Kidney Dis; 2003 Mar 01; 41(3 Suppl 1):S72-5. PubMed ID: 12612957
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.